StockDrifts LogoStockDrifts

Woojung Bio 215380

Company
우정바이오Woojung Bio
Insiders
4
Buys
24
Total Value
₩211M ($147K)
Avg Return
+36.50%
Last Filing
2026-06-09

Woojung Bio (215380) has 24 disclosed insider purchases and 0 disclosed disposals on record, filed by 4 distinct insiders. Together those filings cover ₩211M ($147K) in reported transaction value. The earliest filing StockDrifts holds for Woojung Bio is dated 2024-06-21; the most recent is 2026-06-09. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +36.50%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-06-09BUYMarket Buy
이상수
Sangsu Lee
Managing Director813₩2,465+0.2%₩2M ($1K)
2026-06-05BUYMarket Buy
이상수
Sangsu Lee
Managing Director4.0K₩2,465+0.2%₩10M ($7K)
2026-06-04BUYMarket Buy
함석희
Seokhee Ham
Managing director treatment400₩2,540-3.0%₩1M ($706)
2026-06-04BUYMarket Buy
이상수
Sangsu Lee
Managing Director2.7K₩2,540-3.0%₩7M ($5K)
2026-06-02BUYMarket Buy
이상수
Sangsu Lee
Managing Director2.3K₩2,485-0.8%₩6M ($4K)
2026-06-02BUYMarket Buy
함석희
Seokhee Ham
Managing director treatment1.0K₩2,485-0.8%₩2M ($2K)
2026-06-01BUYMarket Buy
이상수
Sangsu Lee
Managing Director2.2K₩2,570-4.1%₩6M ($4K)
2026-06-01BUYMarket Buy
함석희
Seokhee Ham
Managing director treatment600₩2,570-4.1%₩2M ($1K)
2026-05-29BUYMarket Buy
함석희
Seokhee Ham
Managing director treatment3.0K₩2,605-5.4%₩8M ($5K)
2026-05-29BUYMarket Buy
이상수
Sangsu Lee
Managing Director1.0K₩2,605-5.4%₩3M ($2K)
2025-08-27BUY상속
천세정
cloth washing
vice president2.1M₩1,658+40.8%₩3.6B ($2.5M)
2025-08-27BUY상속
천희정
Cheon Hee-jeong
CEO2.1M₩1,658+40.8%₩3.5B ($2.4M)
2025-06-30BUY기타
천희정
Cheon Hee-jeong
CEO2.0K₩1,777+31.4%₩4M ($2K)
2025-03-28SELL기타
천희정
Cheon Hee-jeong
moving-2.0K₩1,482-57.6%₩3M ($2K)
2024-08-14BUYMarket Buy
천병년
Cheon Byeong-nyeon
CEO500₩1,635+42.8%₩818K ($568)
2024-08-12BUYMarket Buy
천병년
Cheon Byeong-nyeon
CEO2.5K₩1,617+44.4%₩4M ($3K)
2024-08-09BUYMarket Buy
천병년
Cheon Byeong-nyeon
CEO1.0K₩1,621+44.0%₩2M ($1K)
2024-08-08BUYMarket Buy
천병년
Cheon Byeong-nyeon
CEO3.0K₩1,530+52.6%₩5M ($3K)
2024-08-02BUYMarket Buy
천병년
Cheon Byeong-nyeon
CEO2.5K₩1,380+69.2%₩3M ($2K)
2024-07-29BUYMarket Buy
천병년
Cheon Byeong-nyeon
CEO4.0K₩1,433+62.9%₩6M ($4K)
2024-07-25BUYMarket Buy
남영표
Nam Youngpyo
Managing Director13.7K₩1,350+73.0%₩18M ($13K)
2024-07-22BUYMarket Buy
천병년
Cheon Byeong-nyeon
CEO15.0K₩1,520+53.6%₩23M ($16K)
2024-07-18BUYMarket Buy
천병년
Cheon Byeong-nyeon
CEO15.6K₩1,480+57.8%₩23M ($16K)
2024-07-12BUYMarket Buy
천병년
Cheon Byeong-nyeon
CEO10.5K₩1,411+65.5%₩15M ($10K)
2024-07-05BUYMarket Buy
천병년
Cheon Byeong-nyeon
CEO19.7K₩1,410+65.6%₩28M ($19K)
2024-07-04BUYMarket Buy
천병년
Cheon Byeong-nyeon
CEO3.0K₩1,251+86.7%₩4M ($3K)
2024-07-01BUYMarket Buy
천병년
Cheon Byeong-nyeon
CEO21.5K₩1,196+95.2%₩26M ($18K)
2024-06-28BUYMarket Buy
천병년
Cheon Byeong-nyeon
CEO7.1K₩1,237+88.8%₩9M ($6K)
2024-06-21BUY기타
남영표
Nam Youngpyo
Managing Director5.8K₩1,220+91.4%₩7M ($5K)

Frequently asked questions

Who has been buying Woojung Bio stock?
4 distinct insiders have filed 24 disclosed insider purchases in Woojung Bio (215380), most recently on 2026-06-09. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Woojung Bio have?
Woojung Bio has 24 buy-side and 0 sell-side disclosures on record, covering ₩211M ($147K) in total reported value, spanning 2024-06-21 to 2026-06-09.
Where does StockDrifts get Woojung Bio insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Woojung Bio. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.